Bifogade filer
Kurs
-1,77%
Kalender
Est. tid* | ||
2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
2025-11-13 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-30 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2025-05-28 | - | Årsstämma |
2025-05-15 | - | Kvartalsrapport 2025-Q1 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-10-30 | - | Split EXPRS2 40:1 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2024-06-05 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-16 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2023-05-24 | - | Årsstämma |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-03-23 | - | Extra Bolagsstämma 2023 |
2023-02-09 | - | Bokslutskommuniké 2022 |
2022-11-17 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-31 | - | Kvartalsrapport 2022-Q1 |
2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2022-05-25 | - | Årsstämma |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-09-23 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-20 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2019-05-23 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-22 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2018-05-24 | - | Årsstämma |
2018-05-17 | - | Kvartalsrapport 2018-Q1 |
2018-02-07 | - | Bokslutskommuniké 2017 |
2017-11-30 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2017-05-31 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-04-19 | - | Extra Bolagsstämma 2017 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-08 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, August 10, 2022 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces that 136,422 warrants held by employees under the 2019 Warrant Program ("TO2") have been fully exercised, providing ExpreS2ion SEK 656,190. The exercise has increased the number of shares by 136,422 from 37,162,106 to 37,298,528.
At an Extra General Meeting in ExpreS[2]ion held on May 23, 2019, it was resolved to issue warrants as part of an incentive program for employees ("the 2019 Warrant Program", or "TO2"). The program comprised a total of 680,100 warrants, where one (1) warrant entitled to subscription of one (1) share in the Company. 612,084 were subscribed for and allocated to the employees. The warrants stipulated a subscription price of SEK 4.81 per share. The TO2 exercise period is in three months from June 1 through August 31 and is carried out in three tranches during the respective months. The first tranche was announced on July 11 (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-exercise-of-2019-warrant-program,c3599701). The 136,422 warrants cover the second of the three tranches.
Number of shares, share capital and dilution
The new shares in the second tranche have now been registered by the Swedish Companies Registration Office (Sw. Bolagsverket). The number of shares in ExpreS[2]ion has increased by 136,422, from 37,162,106 to 37,298,528 shares. The total share capital amounts to SEK 4,144,280.90. The dilution effect for the company's existing shareholders amounted to approximately 0.37 percent.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com